O	0	10	Comparison
O	11	13	of
B-intervention	14	20	EP2006
O	20	21	,
O	22	23	a
O	24	34	filgrastim
O	35	45	biosimilar
O	45	46	,
O	47	49	to
O	50	53	the
O	54	63	reference
O	63	64	:
O	65	66	a
O	67	72	phase
O	73	76	III
O	76	77	,
O	78	88	randomized
O	88	89	,
O	90	96	double
O	96	97	-
O	97	102	blind
O	103	111	clinical
O	112	117	study
O	118	120	in
O	121	124	the
O	125	135	prevention
O	136	138	of
B-condition	139	145	severe
I-condition	146	157	neutropenia
O	158	160	in
O	161	169	patients
O	170	174	with
O	175	181	breast
O	182	188	cancer
O	189	198	receiving
O	199	215	myelosuppressive
O	216	228	chemotherapy
O	228	229	.

O	230	241	Biosimilars
O	242	244	of
O	245	255	filgrastim
O	256	259	are
O	260	262	in
O	263	273	widespread
O	274	282	clinical
O	283	286	use
O	287	289	in
O	290	296	Europe
O	296	297	.

O	298	302	This
O	303	308	phase
O	309	312	III
O	313	318	study
O	319	327	compares
O	328	338	biosimilar
O	339	349	filgrastim
O	350	351	(
O	351	357	EP2006
O	357	358	)
O	358	359	,
O	360	364	with
O	365	368	the
O	369	371	US
O	371	372	-
O	372	380	licensed
O	381	390	reference
O	391	398	product
O	398	399	,
O	400	408	Neupogen
O	408	409	(
O	409	410	®
O	410	411	)
O	411	412	,
O	413	415	in
B-eligibility	416	422	breast
I-eligibility	423	429	cancer
I-eligibility	430	438	patients
I-eligibility	439	448	receiving
I-eligibility	449	450	(
I-eligibility	450	453	neo
I-eligibility	453	454	)
I-eligibility	454	462	adjuvant
I-eligibility	463	479	myelosuppressive
I-eligibility	480	492	chemotherapy
I-eligibility	493	494	(
I-eligibility	494	497	TAC
I-eligibility	497	498	)
O	498	499	.

O	500	501	A
O	502	507	total
O	508	510	of
B-total-participants	511	514	218
O	515	523	patients
O	524	533	receiving
O	534	535	5
O	536	537	µ
O	537	538	g
O	538	539	/
O	539	541	kg
O	541	542	/
O	542	545	day
O	546	556	filgrastim
O	557	561	over
O	562	565	six
O	566	578	chemotherapy
O	579	585	cycles
O	586	590	were
O	591	601	randomized
O	602	603	1
O	603	604	:
O	604	605	1
O	605	606	:
O	606	607	1
O	607	608	:
O	608	609	1
O	610	614	into
O	615	619	four
O	620	624	arms
O	624	625	.

O	626	629	Two
O	630	634	arms
O	635	643	received
O	644	648	only
O	649	652	one
O	653	660	product
O	661	662	(
O	662	676	nonalternating
O	676	677	)
O	677	678	,
O	679	689	biosimilar
O	690	692	or
O	693	702	reference
O	702	703	,
O	704	707	and
O	708	711	two
O	712	716	arms
O	717	718	(
O	718	729	alternating
O	729	730	)
O	731	739	received
O	740	751	alternating
O	752	762	treatments
O	763	769	during
O	770	774	each
O	775	780	cycle
O	781	782	(
O	782	792	biosimilar
O	793	797	then
O	798	807	reference
O	808	810	or
O	811	815	vice
O	816	821	versa
O	821	822	)
O	822	823	.

O	824	827	The
O	828	835	primary
O	836	839	end
O	840	845	point
O	846	849	was
B-outcome-Measure	850	858	duration
I-outcome-Measure	859	861	of
I-outcome-Measure	862	868	severe
I-outcome-Measure	869	880	neutropenia
I-outcome-Measure	881	882	(
I-outcome-Measure	882	885	DSN
I-outcome-Measure	885	886	)
I-outcome-Measure	887	893	during
I-outcome-Measure	894	899	cycle
I-outcome-Measure	900	901	1
O	901	902	.

O	903	906	The
O	907	915	baseline
O	916	931	characteristics
O	932	936	were
O	937	945	balanced
O	946	953	between
O	954	957	the
O	958	962	four
O	963	972	treatment
O	973	977	arms
O	977	978	.

O	979	993	Noninferiority
O	994	996	of
O	997	1007	biosimilar
O	1008	1014	versus
O	1015	1018	the
O	1019	1028	reference
O	1029	1032	was
O	1033	1045	demonstrated
O	1045	1046	:
B-outcome	1047	1050	DSN
I-outcome	1051	1052	(
I-outcome	1052	1056	days
I-outcome	1056	1057	)
I-outcome	1058	1060	in
I-outcome	1061	1066	cycle
I-outcome	1067	1068	1
O	1069	1072	was
B-iv-cont-mean	1073	1074	1
I-iv-cont-mean	1074	1075	.
I-iv-cont-mean	1075	1077	17
O	1078	1079	±
B-iv-cont-sd	1080	1081	1
I-iv-cont-sd	1081	1082	.
I-iv-cont-sd	1082	1084	11
O	1085	1086	(
O	1086	1096	biosimilar
O	1096	1097	,
O	1098	1099	N
O	1100	1101	=
B-intervention-participants	1102	1105	101
O	1105	1106	)
O	1107	1110	and
B-cv-cont-mean	1111	1112	1
I-cv-cont-mean	1112	1113	.
I-cv-cont-mean	1113	1115	20
O	1116	1117	±
B-cv-cont-sd	1118	1119	1
I-cv-cont-sd	1119	1120	.
I-cv-cont-sd	1120	1122	02
O	1123	1124	(
B-control	1124	1133	reference
O	1133	1134	,
O	1135	1136	N
O	1137	1138	=
B-control-participants	1139	1142	103
O	1142	1143	)
O	1143	1144	,
O	1145	1147	97
O	1147	1148	.
O	1148	1149	5
O	1149	1150	%
O	1151	1161	confidence
O	1162	1170	interval
O	1171	1176	lower
O	1177	1185	boundary
O	1186	1189	for
O	1190	1193	the
O	1194	1204	difference
O	1205	1208	was
O	1209	1210	-
O	1210	1211	0
O	1211	1212	.
O	1212	1214	26
O	1215	1219	days
O	1220	1221	(
O	1221	1226	above
O	1227	1230	the
O	1231	1241	predefined
O	1242	1247	limit
O	1248	1250	of
O	1251	1252	-
O	1252	1253	1
O	1254	1257	day
O	1257	1258	)
O	1258	1259	.

O	1260	1262	No
B-outcome	1263	1273	clinically
I-outcome	1274	1284	meaningful
I-outcome	1285	1296	differences
O	1297	1301	were
O	1302	1310	observed
O	1311	1320	regarding
O	1321	1324	any
O	1325	1330	other
O	1331	1339	efficacy
O	1340	1349	parameter
O	1349	1350	:
B-outcome	1351	1360	incidence
I-outcome	1361	1363	of
I-outcome	1364	1371	febrile
I-outcome	1372	1383	neutropenia
I-outcome	1384	1385	(
I-outcome	1385	1387	FN
I-outcome	1387	1388	)
O	1388	1389	;
B-outcome	1390	1405	hospitalization
I-outcome	1406	1409	due
I-outcome	1410	1412	to
I-outcome	1413	1415	FN
O	1415	1416	;
B-outcome	1417	1426	incidence
I-outcome	1427	1429	of
I-outcome	1430	1440	infections
O	1440	1441	;
B-outcome	1442	1447	depth
I-outcome	1448	1451	and
I-outcome	1452	1456	time
I-outcome	1457	1459	of
I-outcome	1460	1468	absolute
I-outcome	1469	1479	neutrophil
I-outcome	1480	1485	count
I-outcome	1486	1487	(
I-outcome	1487	1490	ANC
I-outcome	1490	1491	)
I-outcome	1492	1497	nadir
O	1498	1501	and
B-outcome	1502	1506	time
I-outcome	1507	1509	to
I-outcome	1510	1513	ANC
I-outcome	1514	1522	recovery
O	1523	1529	during
O	1530	1535	cycle
O	1536	1537	1
O	1538	1541	and
O	1542	1548	across
O	1549	1552	all
O	1553	1559	cycles
O	1559	1560	.

O	1561	1564	The
O	1565	1572	pattern
O	1573	1576	and
O	1577	1586	frequency
O	1587	1589	of
B-outcome	1590	1597	adverse
I-outcome	1598	1604	events
O	1605	1609	were
O	1610	1617	similar
O	1618	1624	across
O	1625	1628	all
O	1629	1639	treatments
O	1639	1640	.

O	1641	1645	This
O	1646	1651	study
O	1652	1664	demonstrates
O	1665	1669	that
O	1670	1680	biosimilar
O	1681	1684	and
O	1685	1688	the
O	1689	1698	reference
O	1699	1709	filgrastim
O	1710	1713	are
O	1714	1721	similar
O	1722	1726	with
O	1727	1729	no
O	1730	1740	clinically
O	1741	1751	meaningful
O	1752	1763	differences
O	1764	1773	regarding
O	1774	1782	efficacy
O	1783	1786	and
O	1787	1793	safety
O	1794	1796	in
O	1797	1807	prevention
O	1808	1810	of
O	1811	1817	severe
O	1818	1829	neutropenia
O	1829	1830	.

O	1831	1841	Biosimilar
O	1842	1852	filgrastim
O	1853	1858	could
O	1859	1868	represent
O	1869	1871	an
O	1872	1881	important
O	1882	1893	alternative
O	1894	1896	to
O	1897	1900	the
O	1901	1910	reference
O	1911	1918	product
O	1918	1919	,
O	1920	1931	potentially
O	1932	1942	benefiting
O	1943	1949	public
O	1950	1956	health
O	1957	1959	by
O	1960	1970	increasing
O	1971	1977	access
O	1978	1980	to
O	1981	1991	filgrastim
O	1992	2001	treatment
O	2001	2002	.

O	2003	2014	NCT01519700
O	2014	2015	.
